INHERENT BIOSCIENCES, INC.
Epigenetic diagnostic test predicting sperm retrieval success in men with non-obstructive azoospermia
- Sector
- Medtech
- Headquarters
- SALT LAKE CITY, UT
- Founded
- 2019
- Latest Form D
- $1.5M, May 2023
- Total capital
- $3.9M
- Federal grants
- $2.4M
- 6 awards · 2020–2025
- Rank in peer group#64 of 112
- Private capital raised
- $1.5M
- 1 Form D · last May 2023
- 41 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 7 pending · first 2024
- Rank in peer group#34 of 112
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for Men with Severe Infertility$50K
- Federal grantHealth and Human S · Phase II · Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for Men with Severe Infertility$805K
- Federal grantHealth and Human S · Phase II · Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for Men with Severe Infertility$762K
- Federal grantHealth and Human S · Phase II · Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for Men with Severe Infertility$270K
- Private capital raisedForm D · SEC · 1st filing$1.5M
- Federal grantHealth and Human S · Phase I · Clinical epigenetic diagnostic for spermatogenic failure and future health risks$255K
- Federal grantNSF · Phase I · SBIR Phase I: Using patient specific DNA methylation to predict COVID-19 clinical prognosis$256K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
33months
from INHERENT BIOSCIENCES, INC.’s first federal award to its first private round.
- First federal award · Aug 2020
- NSF · $256K
- First Form D · May 2023
- $1.5M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 112 peers
Line = medianMedtech · Instrument
- Federal grantsBelow median
- Granted patents#34 · top 30%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andrew OlsonExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 8- PendingMethods and Systems for Predicting Sperm QualityUSPTOApplication 18698414
- PendingDNA Methylation Analysis to Identify Cell TypeUSPTOApplication 18822630
- GrantedDNA Methylation Analysis to Identify Cell TypeUSPTOUS 12,110,559
Show all 8 patent records
- Methods and Systems for Predicting Sperm QualityJun 5, 2025 · Application 18698414Pending
- DNA Methylation Analysis to Identify Cell TypeFeb 13, 2025 · Application 18822630Pending
- DNA Methylation Analysis to Identify Cell TypeOct 8, 2024 · US 12,110,559Granted
- Methylation Analysis for Identifying DiseaseApplication 63291536Pending
- Methods and Systems for Predicting Sperm QualityApplication 63252732Pending
- Cell Free DNA Methylation Analysis to Determine Tissue of Origin: Utility in Male Infertility DiagnosisApplication 63196343Pending
- Methods And Systems For Predicting Sperm QualityApplication PCTUS2022077583Pending
- Dna Methylation Analysis To Identify Cell TypeApplication PCTUS2022032104Pending
Related companies, and why
- Impulse Wellness LLCSimilar federal contract value in Medtech · null in contracts
- Lasarrus Clinic and Research CenterSimilar federal contract value in Medtech · null in contracts
- NVIEW MEDICALSimilar federal contract value in Medtech · null in contracts
- RESILIENT LIFESCIENCE, INC.Similar federal contract value in Medtech · null in contracts
- Springbok, Inc.Similar federal contract value in Medtech · null in contracts
- BIOSIGHT, LLCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .